RNAi-based nanomedicines for targeted personalized therapy

被引:137
作者
Daka, Ala [1 ]
Peer, Dan [1 ]
机构
[1] Tel Aviv Univ, Ctr Nanosci & Nanotechnol, IL-69978 Tel Aviv, Israel
基金
以色列科学基金会;
关键词
Short interfering RNA (siRNA); In vivo; Systemic delivery; Nanoparticles; Clinical trials; Personalized medicine; SMALL INTERFERING RNA; SIRNA DELIVERY-SYSTEM; LIPID-LIKE MATERIALS; SHORT HAIRPIN RNA; IN-VIVO DELIVERY; GENE-EXPRESSION; CARBON NANOTUBES; CHEMICAL-MODIFICATION; MACROMOLECULAR THERAPEUTICS; ANTISENSE OLIGONUCLEOTIDES;
D O I
10.1016/j.addr.2012.08.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting "omics" discipline to personalize RNAi-based therapeutics. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:1508 / 1521
页数:14
相关论文
共 156 条
[31]   THE ROLE OF DIOLEOYL PHOSPHATIDYLETHANOLAMINE IN CATIONIC LIPOSOME-MEDIATED GENE-TRANSFER [J].
FARHOOD, H ;
SERBINA, N ;
HUANG, L .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1995, 1235 (02) :289-295
[32]   Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA [J].
Fattal, Elias ;
Bochot, Amelie .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (11) :1203-1223
[33]  
Felgner P.L., 1993, J CELL BIOCHEM, V269, P2550
[34]   Cancer nanotechnology: Opportunities and challenges [J].
Ferrari, M .
NATURE REVIEWS CANCER, 2005, 5 (03) :161-171
[35]   Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? [J].
Filipowicz, Witold ;
Bhattacharyya, Suvendra N. ;
Sonenberg, Nahum .
NATURE REVIEWS GENETICS, 2008, 9 (02) :102-114
[36]  
Filleur S, 2003, CANCER RES, V63, P3919
[37]   Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses [J].
Forsbach, Alexandra ;
Nemorin, Jean-Guy ;
Montino, Carmen ;
Mueller, Christian ;
Samulowitz, Ulrike ;
Vicari, Alain P. ;
Jurk, Marion ;
Mutwiri, George K. ;
Krieg, Arthur M. ;
Lipford, Grayson B. ;
Vollmer, Joerg .
JOURNAL OF IMMUNOLOGY, 2008, 180 (06) :3729-3738
[38]   Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates [J].
Frank-Kamenetsky, Maria ;
Grefhorst, Aldo ;
Anderson, Norma N. ;
Racie, Timothy S. ;
Bramlage, Birgit ;
Akinc, Akin ;
Butler, David ;
Charisse, Klaus ;
Dorkin, Robert ;
Fan, Yupeng ;
Gamba-Vitalo, Christina ;
Hadwiger, Philipp ;
Jayaraman, Muthusamy ;
John, Matthias ;
Jayaprakash, K. Narayanannair ;
Maier, Martin ;
Nechev, Lubomir ;
Rajeev, Kallanthottathil G. ;
Read, Timothy ;
Roehl, Ingo ;
Soutschek, Juergen ;
Tan, Pamela ;
Wong, Jamie ;
Wang, Gang ;
Zimmermann, Tracy ;
de Fougerolles, Antonin ;
Vornlocher, Hans-Peter ;
Langer, Robert ;
Anderson, Daniel G. ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
Horton, Jay D. ;
Fitzgerald, Kevin .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (33) :11915-11920
[39]   The Effect of Chemical Modification and Nanoparticle Formulation on Stability and Biodistribution of siRNA in Mice [J].
Gao, Shan ;
Dagnaes-Hansen, Frederik ;
Nielsen, Ebbe Juel Bech ;
Wengel, Jesper ;
Besenbacher, Flemming ;
Howard, Kenneth Alan ;
Kjems, Jorgen .
MOLECULAR THERAPY, 2009, 17 (07) :1225-1233
[40]   RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival [J].
Gaudillière, B ;
Shi, Y ;
Bonni, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (48) :46442-46446